|
|
Title | Creator | Description | Identifier |
1 |
|
A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Katz, Bradley J; Antoszyk, A; Singh, RP; Gurses-Ozden, R; Erlich, S; Rothenstein, D; Sharon, N; Hodge, J; Leonard A. Levin, MD, PhD. Chair of Ophthalmology, McGill University; Miller, NR | Subjects with stable low vision due to posterior segment pathology and subjects with acute onset NAION were enrolled in a 2 strata, Phase I, multi-center, open-label, and dose escalation study to determine safety, tolerability, and the structural and functional changes after single IVT injection of ... | 20130212_nanos_sciplatform2_01-1 |
2 |
|
A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | Katz, Bradley J; Antoszyk, A; Singh, RP; Gurses-Ozden, R; Erlich, S; Rothenstein, D; Sharon, N; Hodge, J; Leonard A. Levin, MD, PhD. Chair of Ophthalmology, McGill University; Miller, NR | Subjects with stable low vision due to posterior segment pathology and subjects with acute onset NAION were enrolled in a 2 strata, Phase I, multi-center, open-label, and dose escalation study to determine safety, tolerability, and the structural and functional changes after single IVT injection of ... | 20130212_nanos_sciplatform2_01 |